Novel mTORC1 Inhibitors Kill Glioblastoma Stem Cells

Glioblastoma (GBM) is an aggressive tumor of the brain, with an average post-diagnosis survival of 15 months. GBM stem cells (GBMSC) resist the standard-of-care therapy, temozolomide, and are considered a major contributor to tumor resistance. Mammalian target of rapamycin Complex 1 (mTORC1) regulat...

Descripción completa

Detalles Bibliográficos
Autores principales: Sandoval, Jose A., Tomilov, Alexey, Datta, Sandipan, Allen, Sonia, O’Donnell, Robert, Sears, Thomas, Woolard, Kevin, Kovalskyy, Dmytro, Angelastro, James M., Cortopassi, Gino
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7761300/
https://www.ncbi.nlm.nih.gov/pubmed/33255358
http://dx.doi.org/10.3390/ph13120419

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7761300/
https://www.ncbi.nlm.nih.gov/pubmed/33255358
http://dx.doi.org/10.3390/ph13120419

Ejemplares similares